Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast

Leong, Pooi Pooi; Muhammad, Rohaizak; Ibrahim, Normala; Ithnin, Hairuszah; Abdullah, Maha; Davis, William C.; Seow, Heng Fong

doi:10.1016/j.imlet.2005.09.006

Cited by 62 publications

(42 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with our results, Zhu et al (2015) and Leong et al (2006) have demonstrated an insignificant negative correlation between the CD4+CD25+ cells and CD8+CD28+CD25+ obtained from TILs of breast cancer patients. They also found a significant positive correlation between CD4+CD25+ and CD8+CD28-subsets.…”

supporting

confidence: 94%

Evaluation of T- Regulatory Cells in Breast Cancer.

Ali¹,

Taweel²,

Gawad³

et al. 2017

IJAR

View full text Add to dashboard Cite

supporting

confidence: 94%

Evaluation of T- Regulatory Cells in Breast Cancer.

Ali¹,

Taweel²,

Gawad³

et al. 2017

IJAR

View full text Add to dashboard Cite

“…The intra-tumor mononuclear cell infiltrate consists largely of T-lymphocytes with few B-cells and variable numbers of macrophages and NKcells [4,[41][42][43][44]. In our previous findings, lymphocytes represented the predominant cell type in the tumor infiltrate [12].…”

Section: Discussionmentioning

confidence: 67%

Understanding of the immunological heterogeneity of canine mammary carcinomas to provide immunophenotypic features of circulating leukocytes as clinically relevant prognostic biomarkers

Estrela‐Lima

Araújo²,

Costa-Neto

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

We have evaluated the phenotypic features of peripheral blood leukocytes as putative novel biomarkers with prognostic values to monitor canine mammary carcinomas. Female dogs were categorized into distinct groups, referred as mammary carcinoma in benign mixed tumor-MC-BMT and mammary carcinoma-MC. Our findings demonstrate that decreased percentage of B-cells along with increased frequency of NK-cells, CD8(+)T-cells, and CD8(+)CD5(Low+)T-cells beside higher T/B-cells and lower CD4(+)/CD8(+) ratio were the hallmarks of MC-BMT. Despite the lower expression of MHCI and MHCII, the lymphocytes from MC-BMT and MC displayed higher migration potential as suggested by enhanced frequency of CD18(+) events. Although increased levels of macrophage-like cells/(CD14(+)CD16(+)) and decreased levels of MHCII expression were a common phenotypic feature in mammary carcinoma, down-regulation of MHCI was selectively observed in MC. Decreased frequency of CD4(+) T-cells with increased levels of CD8(+) T-cells and lower CD4(+)/CD8(+) T-cell ratio were relevant biomarkers of MC-BTM(-). Although decreased expression of MHCI by monocytes was observed in MC-BTM regardless of the presence of lymph node metastasis, this phenotypic feature was restricted to MC free of metastasis. The CD4(+)/CD8(+) T-cells ratio lower than 1.8 was elected as a valid parameter with outstanding performance to predict survival in MC-BMT. On the other hand, the MHCI expression by monocytes higher than 10(2) MFI showed good value to estimate worse outcome in MC. These results should help to improve our understanding of the immunological heterogeneity of canine mammary carcinomas and provide tools for the determination of cut-off scores of clinically relevant immonophenotypic prognostic biomarkers.

show abstract

“…Identification of Foxp3-expressing cells by either immunofluorescence or flow cytometry has revealed an enrichment of these cells in ovarian carcinoma, breast carcinoma and lymphoma (Curiel et al, 2004;Roncador et al, 2005;Leong et al, 2006). Likewise, flow cytometric analyses of Foxp3-expressing cells in carcinogeninduced tumours in mice have revealed a significant enrichment of these cells .…”

Section: Tregs: a Conspicuous Presence Within Tumoursmentioning

confidence: 99%

Positive and negative influences of regulatory T cells on tumour immunity

Gallimore

Simon

2008

Oncogene

View full text Add to dashboard Cite

Clinicians and scientists have long questioned whether the immune system has a role in destroying cancerous tissue. Studies performed in animal models have, however, recently revealed that the immune system can, at least in principle, effectively control tumours. In parallel with these findings, a large body of evidence indicates that although the immune system has the capacity to control tumours, there are also regulatory mechanisms that subdue these responses. A major challenge of tumour immunotherapy, therefore, is to find ways of disabling these regulatory functions while restoring or priming any immune responses that are protective.

show abstract

Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast

Cited by 62 publications

References 38 publications

Evaluation of T- Regulatory Cells in Breast Cancer.

Evaluation of T- Regulatory Cells in Breast Cancer.

Understanding of the immunological heterogeneity of canine mammary carcinomas to provide immunophenotypic features of circulating leukocytes as clinically relevant prognostic biomarkers

Positive and negative influences of regulatory T cells on tumour immunity

Contact Info

Product

Resources

About